Ileibacterium valens bacterium and application thereof

Abstract

The invention belongs to the technical field of biology, and discloses an Ileibacterium valens strain and application thereof.The Ileibacterium valens strain has the preservation number of GDMCC No: 67610, the preservation date of January 8, 2026, the classification name of Ileibacterium valens is named as Ileibacterium valens, the preservation unit is Guangdong Microbial Culture Collection Center, the preservation address is 59 building, No.100 Courtyard, Xianlie Middle Road, Guangzhou City, the Ileibacterium valens strain can obviously improve the ornithine level in the liver, and the content of ornithine in the liver can be obviously reduced. The traditional Chinese medicine composition has a certain improvement effect on metabolic disorder, hepatic lesion and fat deposition caused by MASLD induced by high-fat, high-glucose and high-cholesterol diet, and is expressed in that the levels of TC, LDL, AST and ALT in serum can be remarkably reduced.

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to a strain of Ileibacterium valens and its applications. Background Technology

[0002] Metabolic-associated fatty liver disease (MASLD) is a prevalent chronic liver disease closely related to obesity, insulin resistance, and metabolic syndrome. In recent years, with dramatic changes in dietary structure, the widespread adoption of high-fat, high-sugar, and high-cholesterol diets has become a key contributing factor to the continued rise in MASLD incidence. Excessive fat intake directly increases the burden of hepatic lipid synthesis, high sugar promotes de novo lipid synthesis in the liver, exacerbating fat deposition, and high cholesterol further disrupts lipid transport and metabolic balance. These three factors synergistically induce insulin resistance, oxidative stress, and chronic low-grade inflammation. Long-term exposure to this dietary pattern can gradually lead to hepatic steatosis, hepatocyte ballooning degeneration, and lobular inflammation. In severe cases, it can progress to steatohepatitis, liver fibrosis, and even cirrhosis, significantly increasing the risk of liver-related complications.

[0003] Currently, clinical interventions for MASLD are still based on lifestyle modifications, including limiting the intake of high-fat, high-sugar, and high-cholesterol foods, controlling total calorie intake, and regular exercise. However, this strategy relies heavily on high patient adherence, and its clinical effectiveness is often limited. In terms of drug treatment, existing drugs mostly focus on improving insulin resistance or lowering blood lipids. While they can alleviate some symptoms, they suffer from issues such as single-target therapy and unverified long-term safety, making it difficult to meet diverse clinical needs. Therefore, developing safe, effective, and highly adherent new intervention methods has become an urgent need in the prevention and treatment of MASLD.

[0004] The gut microbiota-mediated "gut-hepatic axis" plays a crucial regulatory role in the progression of metastatic atherosclerotic lesions (MASLD). Dysbiosis of the gut microbiota may lead to abnormal hepatic lipid metabolism, thereby promoting the development and progression of MASLD. Studies have found that MASLD patients typically have low gut microbiota diversity, and the abundance of certain specific microbiota may be correlated with the occurrence and severity of MASLD. The gut microbiota directly or indirectly affects hepatic metabolic function through metabolites such as short-chain fatty acids (SCFAs), as disclosed in prior art CN119570671A. Bifidobacterium And the prior art disclosed in CN103764156A Saccharomyces boulardii Gut probiotics have been reported to significantly improve obesity and MASLD symptoms. Adjusting the gut microbiota structure and using probiotics have become new strategies for the prevention and treatment of MASLD.

[0005] *Ileibacterium valens*, belonging to the phylum Firmicutes and family Erysipelotrichaceae, is a Gram-positive, rod-shaped, facultative anaerobic bacterium. It is an intestinal commensal bacterium, primarily found in the human gut, participating in physiological processes such as intestinal immune regulation and nutrient absorption. Recent studies have found a close association between it and the development of colorectal cancer, potentially promoting its progression by altering the small intestinal flora structure, releasing inflammatory factors, and disrupting the intestinal barrier (Fu T, Huan T, Rahman G, et al. Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancerprogression[J]. Cell reports, 2023, 42(8).). However, whether *Ileibacterium valens* has a mitigating effect on metabolic-associated fatty liver disease (MASLD) has not yet been reported. Summary of the Invention

[0006] The purpose of this invention is to provide a strain of Ileibacterium valens that can significantly increase ornithine levels in the liver, and has a certain ameliorative effect on metabolic disorders, liver lesions, and fat deposition caused by MASLD induced by a high-fat, high-sugar, and high-cholesterol diet.

[0007] In addition, the present invention also provides applications and products of this Ileibacterium valens bacterium.

[0008] To achieve the above objectives, the present invention provides the following technical solution: A strain of *Ileibacterium valens*, with accession number GDMCC No: 67610, accession date January 8, 2026, and classified as... Ileibacterium valens, The depository is Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0009] Furthermore, this invention discloses the use of Ileibacterium valens as described above in the preparation of products for alleviating metabolic-associated fatty liver disease.

[0010] Preferably, the active ingredient of the product includes Ileibacterium valens.

[0011] Preferably, the product is a pharmaceutical, probiotic, or nutritional supplement.

[0012] Finally, this invention discloses a product for alleviating metabolic-associated fatty liver disease, wherein the active ingredient of the product includes Ileibacterium valens as described above.

[0013] Preferably, the product is a pharmaceutical, probiotic, or nutritional supplement.

[0014] Compared with the prior art, the beneficial effects of the present invention are: The *Ileibacterium valens* strain provided by this invention can significantly increase ornithine levels in the liver, and has a certain ameliorative effect on metabolic disorders, liver lesions, and fat deposition caused by MASLD induced by a high-fat, high-sugar, and high-cholesterol diet. This is manifested in a significant reduction in serum TC, LDL, AST, and ALT levels. Attached Figure Description

[0015] Figure 1 The results of the glucose tolerance test are shown in the figure. Figure 2 The graph shows the results of an insulin sensitivity test. Figure 3 Comparison of livers between mice in group H and group N; Figure 4 The image shows the results of HE staining, where a represents group N and b represents group H. Figure 5 Figure showing the results of quantitative analysis of inflammatory cell counts in mouse liver; Figure 6 The image shows the results of Oil Red O staining of mouse livers, where a represents group N and b represents group H. Figure 7 Figure showing the results of quantitative analysis of lipid droplet area, average lipid droplet size, and lipid droplet number density in mouse liver; Figure 8 A graph showing the differences in cecal microbial alpha diversity (Shannon index) between groups; Figure 9 Principal coordinate analysis (PCoA) plot of cecal microbial Beta diversity; Figure 10 Figure showing the species abundance difference analysis of Ileibacterium valens; Figure 11 The graph shows the results of metabolite analysis in the liver. In the graph, a is the score graph of orthogonal partial least squares discriminant analysis (OPLS-DA) of liver non-target metabolome, b is the permutation test graph of OPLS-DA model of liver non-target metabolome, and c is the volcano plot of differential metabolites in the liver. Figure 12The figure shows the detection results of ornithine content in Example 3. In the figure, a is the chromatogram of LC-QQQ-MS / MS MRM mode (ion pair 147.0→84.0), b is the chromatogram of LC-QQQ-MS / MS MRM dual ion pair mode (147.0→84.0, 147.0→130.0), c is the mass spectrum of LC-QQQ-MS / MS MRM mode, and d is the bar chart of ornithine content comparison between groups. Figure 13 The graph shows the correlation between Ileibacterium valens and ornithine. Figure 14 Figure 1 shows the results of a glucose tolerance test in mice after Ileibacterium valens transplantation. Figure 15 Figure 1 shows the results of an insulin sensitivity experiment in mice after Ileibacterium valens transplantation. Figure 16 Image showing HE staining results of mouse livers after Ileibacterium valens transplantation; Figure 17 The graph shows the results of ornithine content in the cecal chyme of mice after Ileibacterium valens transplantation. Figure 18 The figure shows the results of ornithine content detection. In the figure, a is the chromatogram of LC-QQQ-MS / MS MRM mode (ion pair 133.0→70.0), b is the chromatogram of LC-QQQ-MS / MS MRM dual ion pair mode (133.0→70.0, 133.0→116.0), and c is the mass spectrum of LC-QQQ-MS / MS MRM mode. Figure 19 The figures show the results of various indicators in mouse serum. In the figures, a) represents the total cholesterol (TC) content in mouse serum; b) represents the triglyceride (TG) content in mouse serum; c) represents the low-density lipoprotein (LDL) content in mouse serum; d) represents the aspartate aminotransferase (AST) content in mouse serum; e) represents the alanine aminotransferase (ALT) content in mouse serum; and f) represents the alkaline phosphatase (ALP) content in mouse serum. Detailed Implementation

[0016] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0017] Animal feeding methods: Eighteen 5-week-old male C57BL / 6J mice were purchased from Zhiyuan (Guangzhou) Biomedical Technology Co., Ltd. All mice were housed in a pathogen-free room at 25℃, 60% relative humidity, and a 12-hour light-dark cycle. After three weeks of pre-feeding in this environment, all mice were randomly divided into two groups: a normal diet group (N group) fed a maintenance diet for laboratory mice; and a high-fat, high-sugar, high-cholesterol diet group (H group) fed a high-fat, high-sugar, high-cholesterol diet.

[0018] Example 1 At the end of week 8, six mice from each group were randomly selected for a glucose tolerance test. The specific procedures were as follows: Before the experiment, mice were weighed and trained by tail clipping to avoid hyperglycemia due to tail clipping stress during the actual experiment. The glucose gavage dose was 2g / kg. Mice were fasted but allowed water for 16 hours. During the experiment, the water bottle was removed, and blood glucose levels were recorded at 0, 15, 30, 60, and 120 minutes. Blood glucose was measured at 0:00 (0:00) by cutting off approximately 1-2 mm of the mouse's tail with sterilized small scissors. After tail clipping, the tail was gently squeezed to allow blood to flow out. The first drop of blood was discarded to avoid potential contamination with tissue fluid, affecting the accuracy of the measurement. The second drop of blood was immediately measured using a blood glucose meter. Immediately after the first mouse was gavaged, a 15-minute countdown was started. Blood samples were collected at 15, 30, 60, and 120 minutes after gavage, with gentle squeezing of the tail. Disinfection and hemostasis were performed after each blood collection. Blood glucose levels were immediately measured using a blood glucose meter. Feed was replenished promptly after the experiment. Results are as follows: Figure 1 As shown, the blood glucose levels of mice in group H continued to rise from 0 to 30 minutes and began to decline after 30 minutes, while the blood glucose levels of mice in group N began to decline after 15 minutes.

[0019] At the end of week 9, six mice from each group were randomly selected for the insulin sensitivity test. The specific procedures were as follows: Preparation was the same as for the glucose tolerance test. Insulin was administered intraperitoneally at a dose of 0.5 U / kg aspart insulin solution. Mice were fasted but allowed water for 4 hours. During the test, the water bottle was removed, and blood glucose levels were recorded at 0, 15, 30, 60, and 120 minutes. The mice's condition was continuously monitored during blood glucose monitoring. If blood glucose levels fell below 3 mmol / L, the mice were immediately resuscitated with an intraperitoneal injection of 20% glucose solution. The affected mouse was then excluded from the test and placed in an empty cage to observe its recovery. Results are as follows: Figure 2 As shown, at 0 min (after 4 h of fasting), the blood glucose level in group H mice was significantly higher than that in group N. 15 min after insulin injection, the blood glucose level in group H mice was significantly higher than that in group N. The area under the curve (AUC) also reflects that the AUC in group H was significantly higher than that in group N.

[0020] At the end of week 10, mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital. Blood was collected under anesthesia using the enucleation method and placed in anticoagulant-free centrifuge tubes. After standing at room temperature for 2 hours, the tubes were centrifuged at 3000 rpm for 20 minutes at 4°C. The supernatant was the serum, which was stored at -80°C. The collected liver tissue was divided into two parts: the first part was fixed with 4% paraformaldehyde solution for HE staining and Oil Red O staining analysis; the second part was frozen in liquid nitrogen and stored at -80°C for non-targeted metabolomics analysis. The results are as follows: Figures 3-7 As shown, comparing the livers of mice in group H and group N, it was found that the livers of mice in group H were pale yellow, while the livers of mice in group N were normal in size and color. Figure 3 HE staining results showed that in group N, the liver lobule structure was intact, the hepatocytes were arranged in cords, a small number of lymphocytes were visible, the nuclear membranes were intact, the nucleoli were clear, and no fat vacuoles were observed; in group H, the hepatocytes were arranged randomly, and lipid droplets of varying sizes were visible, with obvious inflammatory cell aggregation and diffuse infiltration of neutrophils and eosinophils. Figure 4 Quantitative analysis of inflammatory cell counts revealed that the number of inflammatory cells in the liver was significantly higher in group H compared to group N. Figure 5 Oil Red O staining results showed that large areas of lipid droplets appeared in the hepatocytes of group H. Figure 6 Further quantitative analysis of lipid droplet area, average lipid droplet size, and lipid droplet number density revealed that the lipid droplet area in group H was significantly larger than that in group N. Figure 7 ).

[0021] The above results indicate that a high-fat, high-sugar, and high-cholesterol diet can induce lipid accumulation in the liver and cause disorders in glucose and lipid metabolism.

[0022] Example 2 Mouse cecal chyme samples were collected in sterile cryovials, flash-frozen in liquid nitrogen, and stored at -80°C for metagenomic sequencing analysis.

[0023] DNA extraction was performed using the FastPure Stool DNA Isolation Kit (Magnetic bead) (MJYH, Shanghai, China). After extraction, DNA concentration and purity were assessed, and DNA integrity was checked using 1% agarose gel electrophoresis. DNA fragmentation was performed using a Covaris M220 (Genetron Health, China), selecting fragments of approximately 350 bp for PE library construction. Quality control, OTU clustering, species taxonomic annotation, and microbial community diversity analysis of the sequencing data were performed using the QIIME2 software package and R (version 4.3.0).

[0024] The results are as follows Figures 8-10As shown, the Shannon index is used to assess Alpha diversity ( Figure 8 The results showed that the cecal microbial diversity in group H was significantly lower than that in group N. Principal coordinate analysis (PCoA) Figure 9 The study used LEfSe to assess changes in cecal microbiota structure within and between groups, showing good aggregation within groups and clear differentiation between groups, indicating that a high-fat, high-sugar, and high-cholesterol diet can cause changes in cecal microbiota structure. Differential bacterial analysis was performed using LDA > 4 and P < 0.05 as screening criteria. Figure 10 As shown in the results of the difference analysis between the two groups, the abundance of Ileibacterium valens was significantly reduced in group H compared with group N.

[0025] Example 3 To assess the effects of a high-fat, high-sugar, and high-cholesterol diet on liver metabolism, non-targeted metabolomics techniques were employed to analyze metabolites in the liver. Liver tissue was pretreated and then chromatographically separated into target compounds using a Vanquish (Thermo Fisher Scientific) ultra-high performance liquid chromatograph (UPLC) with a Waters ACQUITY UPLC BEH Amide column (2.1 mm × 50 mm, 1.7 μm). Phase A of the HPLC was aqueous, containing 25 mmol / L ammonium acetate and 25 mmol / L ammonia, while Phase B was acetonitrile. Sample tray temperature: 4 °C; injection volume: 2 μL. An Orbitrap Exploris 120 mass spectrometer was used for primary and secondary mass spectrometry data acquisition under the control of software (Xcalibur, version 4.4, Thermo). Detailed parameters are as follows: sheath gas flow rate 50 Arb, auxiliary gas flow rate 15 Arb, capillary temperature 320℃, full scan mass spectrometry resolution 60000, tandem mass spectrometry resolution 15000, collision energy SNCE 20 / 30 / 40, spray voltage 3.8kV (positive ion mode) or -3.4kV (negative ion mode).

[0026] The results were analyzed using orthogonal partial least squares-discriminant analysis (OPLS-DA) to assess overall metabolic differences among different samples; the results are as follows: Figure 11 As shown, groups N and H exhibit obvious clustering ( Figure 11 (a) The permutation test results indicate that the model is not overfitting. Figure 11 (b) Further screening of differentially expressed metabolites, such as volcano plots ( Figure 11As shown in c), 54 differentially regulated metabolites (FC > 1 and P < 0.05) and 254 differentially regulated metabolites (FC < 1 and P < 0.05) were identified. Further screening of potential active metabolites was conducted using a VIP value > 1. By excluding exogenous substances, ornithine, xanthine nucleoside, N-acetyl-L-phenylalanine, N-acetylornithine, trigonelline, DL-threonine methyl ester, dopamine 4-β-D-glucuronic acid, dioleoylphosphatidylcholine, and alanine-aspartic acid were identified as potential active metabolites.

[0027] Ornithine in the sample was quantitatively detected using liquid chromatography-triple quadrupole tandem mass spectrometry (LC-QQQ-MS / MS). Sample pretreatment was as follows: Liver tissue was accurately weighed, and acetonitrile (containing 0.1% formic acid) was added at a ratio of 1:9 (w / v) to precipitate the protein. After centrifugation, the supernatant was collected, purged with nitrogen, and reconstituted with the initial mobile phase before membrane analysis. LC and mass spectrometry conditions were as follows: The target analyte was separated using an ECLIPSE PLUS C18 column (2.1×100 mm, 1.8 μm, Agilent). Multiple reaction monitoring (MRM) mode was used for signal acquisition. The characteristic ion pair of ornithine, "147.0→84.0", was selected as the quantitative ion pair. After signal smoothing, the chromatographic response peak of the target analyte was obtained. Figure 12 (a) Ornithine's retention time under this ion pair is approximately 1.163 min. The chromatographic peak is symmetrical and exhibits high response intensity, indicating that these chromatographic conditions can effectively separate and acquire ornithine. To ensure the specificity of the detection results, the MRM signal of another characteristic ion pair of ornithine, "147.0→130.0", was simultaneously acquired, and the chromatograms of the two ion pairs were superimposed. Figure 12 (b) in the middle. Figure 12 The two ion pairs showed consistent retention times and a response ratio of 34.94 (corresponding to 94.5%), consistent with the characteristic ion pair response ratio pattern of the target analyte, confirming that the detection signal originated from ornithine and eliminating false positive interference. Within the MRM detection time period (1.070-1.516 min), the response intensity of ornithine corresponding to characteristic mass-to-charge ratios (84.0, 130.0, 147.0) was statistically analyzed. Figure 12 (c) The results showed that the response intensities of each characteristic mass-to-charge ratio had characteristic differences, with the highest response intensity observed in the parent ion mass-to-charge ratio of 147.0, further verifying the structural characteristics of the target analyte and providing auxiliary evidence for qualitative analysis. Statistical analysis was performed on the ornithine detection results of the N and H group samples ( Figure 12 (d) The results showed that the ornithine content in the liver of group H was significantly lower than that of group N. A combined analysis of the gut microbiome and metabolome was performed, and Spearman correlation analysis was used to assess significant changes in the gut microbiota and metabolites, such as... Figure 13As shown, ornithine and Ileibacterium valens are positively correlated with each other, with a correlation coefficient of 0.6485 (P=0.04254).

[0028] The above data collectively reveal that host ornithine metabolism dysregulation induced by a high-fat, high-sugar, and high-cholesterol diet is closely related to a decrease in the abundance of Ileibacterium valens in the gut.

[0029] Example 4 To investigate the effects of *Ileibacterium valens* on MASLD mice, the experiment was divided into four groups: N group (normal diet), H group (high-fat, high-sugar, high-cholesterol diet), IV group (high-fat, high-sugar, high-cholesterol diet + *Ileibacterium valens*), and EC group (high-fat, high-sugar, high-cholesterol diet + *E. coli*). Mice were induced to develop a MASLD model through a high-fat, high-sugar, high-cholesterol diet. After 10 weeks, N and H groups were administered PBS by gavage, while IV group was administered *Ileibacterium valens* bacterial suspension resuspended in PBS (1×10⁻⁶). 9 CFU / mL), E coli bacterial suspension resuspended in PBS after gavage in the EC group (1×10⁻⁶ CFU / mL), 9 CFU / mL), lasting for 4 weeks, each mouse was administered 0.2 mL by gavage, once daily for the first 2 weeks and once every 2 days for the last 2 weeks. At the end of the experimental period, glucose tolerance (experimental procedure as in Example 1), insulin sensitivity (experimental procedure as in Example 1), liver pathological changes, and fat deposition were measured in the mice. Glucose tolerance results showed ( Figure 14 Insulin sensitivity results showed that the increase in blood glucose levels in groups H and EC was greater than that in groups N and IV, and the AUC in groups H and EC was higher than that in groups N and IV. Figure 15 At 0 min (after 4 h of fasting), the blood glucose levels in mice in groups H and EC were higher than those in groups N and IV, and the AUC in groups H and EC were higher than those in groups N and IV. HE staining results showed that ( Figure 16 In group N, the liver lobule structure was intact, the hepatocyte cords and sinusoids were regularly arranged, the hepatocyte cytoplasm was uniformly stained, and no obvious inflammatory cell infiltration was observed. Group H showed diffuse macrovesicular hepatocyte steatosis, with cell nuclei compressed to the cell margins, disordered hepatocyte cord arrangement, and no obvious inflammatory infiltration. Group IV showed significantly improved hepatic steatosis, with only scattered, small fat vacuoles, basically normal hepatocyte cord arrangement, uniform cytoplasmic staining, and no obvious inflammatory cell infiltration. Group EC showed macrovesicular and mixed hepatocyte steatosis, with hepatocyte swelling in some areas. The ornithine content in the cecal chyme was detected by LC-QQQ-MS / MS, using the same method as in Example 3. The results showed ( Figure 17The ornithine content in the cecal digest of mice in group H was significantly higher than that in group N, while the ornithine content in the cecal digest of mice in group IV was significantly lower than that in group H, indicating that the absorption of ornithine in the intestines of mice in group H was significantly lower than that in groups N and IV.

[0030] The above results indicate that Ileibacterium valens has a certain ameliorative effect on metabolic disorders, liver lesions and fat deposition in MASLD mice, and the absorption of ornithine in the intestine of MASLD mice is significantly lower than that in the N group and IV group.

[0031] Example 5 To verify whether *Ileibacterium valens* can produce ornithine, the ornithine content in the *Ileibacterium valens* culture medium was detected using LC-QQQ-MS / MS, following the same detection method as in Example 3. Figure 18 As shown, signals were detected at m / z 133.0, 116.0, and 70.0, indicating that the bacterial culture contains ornithine, meaning that Ileibacterium valens can produce ornithine. Substituting these values ​​into the standard curve, the ornithine content in the culture medium was calculated to be 214.9214 ng / mL.

[0032] Figure 18 The figure shows the detection results of ornithine content in Example 5. In the figure, a is the chromatogram of LC-QQQ-MS / MS MRM mode (ion pair 133.0→70.0), b is the chromatogram of LC-QQQ-MS / MS MRM dual ion pair mode (133.0→70.0, 133.0→116.0), and c is the mass spectrum of LC-QQQ-MS / MS MRM mode.

[0033] Example 6 The potential protective effect of ornithine against MASLD induced by a high-fat, high-sugar, and high-cholesterol diet is investigated as follows: Ornithine intervention groups: Low-dose ornithine (OA) group 0.75 mg / mL, medium-dose ornithine (OB) group 1.5 mg / mL, and high-dose ornithine (OC) group 3 mg / mL. After inducing a high-fat, high-sugar, and high-cholesterol diet for 10 weeks, ornithine was added to the drinking water daily for 30 days. Serum levels of TC, TG, LDL, AST, ALT, and ALP were measured in each group of mice. The results are as follows: Figure 19 As shown, compared with group N, the serum levels of TC, LDL, AST, and ALT in group H were significantly increased, while the levels of TC, LDL, AST, and ALT decreased to varying degrees after ornithine was added to the drinking water. This indicates that compared with group H mice, ornithine supplementation improves liver function in mice, as evidenced by a significant decrease in serum TC, LDL, AST, and ALT levels.

[0034] The above results indicate that ornithine produced by Ileibacterium valens can improve metabolic disorders and liver fat deposition in MASLD model mice induced by a high-fat, high-sugar, and high-cholesterol diet.

[0035] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the invention. Therefore, the embodiments should be considered in all respects as exemplary and non-limiting, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, it is intended that all variations falling within the meaning and scope of equivalents of the claims be included within the present invention.

Claims

1. A strain of *Ileibacterium valens*, characterized in that, The *Ileibacterium valens* strain described has the accession number GDMCC No: 67610, the accession date is January 8, 2026, and is classified as follows: Ileibacterium valens, The depository is Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

2. The use of Ileibacterium valens as described in claim 1 in the preparation of products for alleviating metabolic-associated fatty liver disease.

3. The application according to claim 2, characterized in that, The active ingredient of the product includes Ileibacterium valens as described in claim 1.

4. The application according to claim 2, characterized in that, The product in question is a pharmaceutical, probiotic, or nutritional supplement.

5. A product for alleviating metabolic-related fatty liver disease, characterized in that, The active ingredient of the product includes Ileibacterium valens as described in claim 1.

6. The product according to claim 5, characterized in that, The product in question is a pharmaceutical, probiotic, or nutritional supplement.

Images